Thrombin peptide Chrysalin® stimulates healing of diabetic foot ulcers in a placebo-controlled phase I/II study

Wound Repair and Regeneration

Volumn 15, Issue 1, 2007, Pages 23-34

  Fife, Caroline ^a   Mader, Jon T ^b   Stone, Jeffery ^c   Brill, Leon ^c   Satterfield, Kathleen ^d   Norfleet, Andrea ^b,e,f   Zwernemann, Amber ^b   Ryaby, James T ^e   Carney, Darrell H ^b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c Limb Salvage Center   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e OrthoLogic Corporation   (United States)

^f GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHRYSALIN; PLACEBO; THROMBIN; TP 508; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC FOOT; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EDEMA; ERYTHEMA; FEMALE; HUMAN; INCIDENCE; MALE; MULTICENTER STUDY; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ULCER HEALING; WOUND CLOSURE;

ADULT; AGED; DIABETIC FOOT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PILOT PROJECTS; PROSPECTIVE STUDIES; THROMBIN; TREATMENT OUTCOME; WOUND HEALING;

EID: 33846434456     PISSN: 10671927     EISSN: 1524475X     Source Type: Journal    
DOI: 10.1111/j.1524-475X.2006.00181.x     Document Type: Article

References (38)

1. Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care 2003; 26: 1790-5.
2. Harrington C, Zagari MJ, Corea J, Klitenic J. A cost analysis of diabetic lower-extremity ulcers. Diabetes Care 2000; 23: 1333-8.
3. Girod I, Valensi P, Laforet C, Moreau-Defarges T, Guillon P, Baron F. An economic evaluation of the cost of diabetic foot ulcers: results of a retrospective study on 239 patients. Diabetes Metab 2003; 293: 269-77.
4. Redekop WK, Stolk EA, Kok E, Lovas K, Kalo Z, Busschbach JJ. Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments. Diabetes Metab 2004; 30: 549-56.
5. Mustoe T. Understanding chronic wounds: a unifying hypothesis on their pathogenesis and implications for therapy. Am J Surg 2004; 187: 65S-70S.
6. Jeffcoate WJ, Harding KG. Diabetic foot ulcers. Lancet 2003; 361: 1545-51.
7. Greenhalgh DG. Wound healing and diabetes mellitus. Clin Plast Surg 2003; 30: 37-45.
8. Cosentino F, Luscher T. Endothelial dysfunction in diabetes mellitus. J Cardiovasc Pharmacol 1998; 32: 54-61.
9. Jude EB, Tentolouris N, Appleton I, Anderson S, Boulton AJ. Role of neuropathy and plasma nitric oxide in recurrent neuropathic and neuroischemic diabetic foot ulcers. Wound Repair Regen 2001; 9: 353-9.
10. Trengove NJ, Stacey MC, MacAuley S, Bennett N, Gibson J, Burslem F, Murphy G, Schultz G. Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Repair Regen 1999; 7: 442-52.
11. Lobmann R, Ambrosch A, Schultz G, Waldmann K, Schiweck S, Lehnert H. Expression of matrix-metalloproteinases and their inhibitors in the wounds of diabetic and non-diabetic patients. Diabetologia 2002; 45: 1011-6.
12. Wall SJ, Sampson MJ, Levell N, Murphy G. Elevated matrix metalloproteinase-2 and -3 production from human diabetic dermal fibroblasts. Br J Dermatol 2003; 149: 13-6.
13. Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diabetes Care 1998; 21: 822-7.
14. Smiell JM, Wieman TJ, Steed DL, Perry BH, Sampson AR, Schwab BH. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies. Wound Repair Regen 1999; 7: 335-46.
15. Steed DL, Donohoe D, Webster MW, Lindsley L. Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. Diabetic Ulcer Study Group. J Am Coll Surg 1996; 183: 61-4.
16. Glenn KC, Frost GH, Bergmann JS, Carney DH. Synthetic peptides bind to high-affinity thrombin receptors and modulate thrombin mitogenesis. Peptide Res 1988; 1: 65-73.
17. Carney DH, Cunningham DD. Cell surface action of thrombin is sufficient to initiate division of chick cells. Cell 1978; 14: 811-23.
18. Carney DH, Cunningham DD. Role of specific cell surface receptors in thrombin-stimulated cell division. Cell 1978; 15: 1341-9.
19. Carney DH, Bergmann JS. 125I-thrombin binds to clustered receptors on noncoated regions of mouse embryo cell surfaces. J Cell Biol 1982; 95: 697-703.
20. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000; 407: 258-64.
21. Carney DH, Stiernberg J, Fenton JW II. Initiation of proliferative events by human alpha-thrombin requires both receptor binding and enzymic activity. J Cell Biochem 1984; 26: 181-95.
22. Carney DH, Herbosa GJ, Stiernberg J, Bergmann JS, Gordon EA, Scott D, Fenton JW II. Double-signal hypothesis for thrombin initiation of cell proliferation. Semin Thromb Hemost 1986; 12: 231-40.
23. Carney DH. Postclotting cellular effects of thrombin mediated by interaction with high-affinity thrombin receptors. In: Berliner L, editor. Thrombin Structure and Function. New York: Plenum, 1992: 351-96.
24. Carney DH, Redin W, McCroskey L. Role of high-affinity thrombin receptors in postclotting cellular effects of thrombin. Semin Thromb Hemost 1992; 18: 91-103.
25. Carney DH, Mann R, Redin WR, Pernia SD, Berry D, Heggers JP, Hayward PG, Robson MC, Christie H, Annable C, Fenton JW II, Glenn KC. Enhancement of incisional wound healing and neovascularization in normal rats by thrombin and synthetic thrombin receptor-activating peptides. J Clin Invest 1992; 89: 1469-77.
26. Cromack DT, Porras RBH, Wee SS, Glenn KC, Purdy JA, Carney DH, Mustoe TA. Acceleration of soft tissue repair by a thrombin-derived oligopeptide. J Surg Res 1992; 53: 117-22.
27. Stiernberg J, Norfleet AM, Redin WR, Warner WS, Fritz RR, Carney DH. Acceleration of full-thickness wound healing in normal rats by the synthetic thrombin peptide, TP508. Wound Repair Regen 2000; 8: 204-15.
28. Norfleet AM, Huang Y, Sower LE, Redin WR, Fritz RR, Carney DH. Thrombin peptide TP508 accelerates closure of dermal excisions in animal tissue with surgically induced ischemia. Wound Repair Regen 2000; 8: 517-29.
29. Norfleet AM, Bergmann JS, Carney DH. Thrombin peptide, TP508, stimulates angiogenic responses in animal models of dermal wound healing, in chick chorioallantoic membranes, and in cultured human aortic and microvascular endothelial cells. Gen Pharmacol 2000; 35: 249-54.
30. Wang H, Li X, Tomin E, Doty SB, Lane JM, Carney DH, Ryaby JT. Thrombin peptide (TP508) promotes fracture repair by up-regulating inflammatory mediators, early growth factors, and increasing angiogenesis. J Orthop Res 2005; 23: 671-79.
31. Sheller MR, Crowther RS, Kinney JH, Yang J, Di Jorio S, Breunig T, Carney DH, Ryaby JT. Repair of rabbit segmental defects with the thrombin peptide, TP508. J Orthop Res 2004; 22: 1094-9.
32. Li G, Ryaby JT, Carney DH, Wang H. Bone formation is enhanced by thrombin-related peptide TP508 during distraction osteogenesis. J Orthop Res 2005; 23: 196-202.
33. Wagner FW. The dysvascular foot: a system of diagnosis and treatment. Foot Ankle 1981; 2: 64-122.
34. Gilman TH. Parameter for measurement of wound closure. Wounds 1990; 3: 95-101.
35. Gorin DR, Cordts PR, LaMorte WW, Menzoian JO. The influence of wound geometry on the measurement of wound healing rates in clinical trials. J Vasc Surg 1996; 23: 524-8.
36. Younes NA, Albsoul AM, Awad H. Diabetic heel ulcers: a major risk factor for lower extremity amputation. Ostomy Wound Manage 2004; 50: 50-60.
37. Hampton S. The complexities of heel ulcers. Nurs Stand 2003; 17: 68-70, 72, 74.
38. Marston WA, Hanft J, Norwood P, Pollak R. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care 2003; 26: 1701-5.